Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York. Show more

Location: 19 Vestry Street, New York, NY, 10013, United States | Website: https://brightmindsbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

181.3M

52 Wk Range

$0.94 - $79.02

Previous Close

$24.81

Open

$24.60

Volume

18,078

Day Range

$24.60 - $25.66

Enterprise Value

129.4M

Cash

55.68M

Avg Qtr Burn

-1.036M

Insider Ownership

22.55%

Institutional Own.

74.12%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.